301 related articles for article (PubMed ID: 22510259)
1. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.
Beck A; Sanglier-Cianférani S; Van Dorsselaer A
Anal Chem; 2012 Jun; 84(11):4637-46. PubMed ID: 22510259
[TBL] [Abstract][Full Text] [Related]
2. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
4. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.
Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion.
Qian J; Liu T; Yang L; Daus A; Crowley R; Zhou Q
Anal Biochem; 2007 May; 364(1):8-18. PubMed ID: 17362871
[TBL] [Abstract][Full Text] [Related]
6. A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry.
Saba JA; Kunkel JP; Jan DC; Ens WE; Standing KG; Butler M; Jamieson JC; Perreault H
Anal Biochem; 2002 Jun; 305(1):16-31. PubMed ID: 12018942
[TBL] [Abstract][Full Text] [Related]
7. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
[TBL] [Abstract][Full Text] [Related]
8. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
9. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.
Ayoub D; Jabs W; Resemann A; Evers W; Evans C; Main L; Baessmann C; Wagner-Rousset E; Suckau D; Beck A
MAbs; 2013; 5(5):699-710. PubMed ID: 23924801
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry.
Janin-Bussat MC; Tonini L; Huillet C; Colas O; Klinguer-Hamour C; Corvaïa N; Beck A
Methods Mol Biol; 2013; 988():93-113. PubMed ID: 23475716
[TBL] [Abstract][Full Text] [Related]
11. A global comparability approach for biosimilar monoclonal antibodies using LC-tandem MS based proteomics.
Chen SL; Wu SL; Huang LJ; Huang JB; Chen SH
J Pharm Biomed Anal; 2013 Jun; 80():126-35. PubMed ID: 23563225
[TBL] [Abstract][Full Text] [Related]
12. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
13. Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates.
Su D; Ng C; Khosraviani M; Yu SF; Cosino E; Kaur S; Xu K
Anal Chem; 2016 Dec; 88(23):11340-11346. PubMed ID: 27779866
[TBL] [Abstract][Full Text] [Related]
14. Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry.
Yan B; Valliere-Douglass J; Brady L; Steen S; Han M; Pace D; Elliott S; Yates Z; Han Y; Balland A; Wang W; Pettit D
J Chromatogr A; 2007 Sep; 1164(1-2):153-61. PubMed ID: 17640657
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody: the corner stone of modern biotherapeutics.
Xia ZN; Cai XT; Cao P
Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
[TBL] [Abstract][Full Text] [Related]
17. Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization.
Terral G; Beck A; Cianférani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():79-90. PubMed ID: 27108304
[TBL] [Abstract][Full Text] [Related]
18. The state-of-play and future of antibody therapeutics.
Elgundi Z; Reslan M; Cruz E; Sifniotis V; Kayser V
Adv Drug Deliv Rev; 2017 Dec; 122():2-19. PubMed ID: 27916504
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry for structural characterization of therapeutic antibodies.
Zhang Z; Pan H; Chen X
Mass Spectrom Rev; 2009; 28(1):147-76. PubMed ID: 18720354
[TBL] [Abstract][Full Text] [Related]
20. The NISTmAb Reference Material 8671 lifecycle management and quality plan.
Schiel JE; Turner A
Anal Bioanal Chem; 2018 Mar; 410(8):2067-2078. PubMed ID: 29430600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
